

Antiviral Library

HBV Subset


Focus on non-nucleoside compounds

YAI, Feb, 2015

Reference Compounds

examples


Isosteric transformations



WO 2014106019

HBV replication inhibition in immortalized murine hepatocyte (AML12)-derived stable cell line (AML12HBV10) and liver Hep DES19 cells ($EC_{50} < 1 \mu\text{M}$) in MTT assays.

Baruch S Blumberg Institute



WO 2015011281

HBV replication inhibition in human hepatoma HepG2.2.15 ($EC_{50} < 0.004 \mu\text{M}$) and HepG2.117 ($EC_{50} = 0.002 \mu\text{M}$) cells in in vitro assays without cytotoxicity against HepG2 cells ($CC_{50} > 100 \mu\text{M}$) in resazurin assays

Janssen R&D Ireland




WO 2014033167

HBV replication inhibition $EC_{50} = 0.21$ and $0.62 \mu\text{M}$, in HepG2.2.15 and HepG2.117 cells, respectively



WO 2014161888


activity against human hepatoma Hep G2.2.15 (stably transfected with HBV genome) and Hep G2.117 (stably inducible HBV producing cell line) cells ($EC_{50} = 0.065$ and $0.091 \mu\text{M}$, respectively).



CN 103664897 (2014)

high diversity HBV DNA replication inhibition (98% at 500 nM) in human hepatoma HepG2.2.15 cells in a qPCR-based assay.


HEC Pharm



CN 103864699 (2014)

Reverse transcriptase inhibitors inhibit HIV-1 reverse transcriptase HBV with an $IC_{50} = 0.41 \mu\text{M}$ (in human liver HepG2 2.2.15 cancer cell)


Peking University




CN 103739597 (2014)

significant antiviral activity against HBsAg, HBeAg antigens and inhibited HBV DNA replication ($IC_{50} = 121.49, 19.73$ and 23.51 mCM , respectively) in human hepatoma Hep G2.2.15 cells without showing any significant cytotoxicity ($CC_{50} = 2466.06 \text{ mCM}$) in MTT assays.

Kunming Institute of Botany




sanguinarine derivatives
CN 103360402 (2014)



WO 2014184350


HBV replication inhibition in human hepatoma HepG2.2.15 and HepG2.117 cells ($EC_{50} < 0.005$ and $0.005 \mu\text{M}$, respectively). It showed no cytotoxicity against HepG2 cells ($CC_{50} > 100 \mu\text{M}$ upon 4 days incubation), in resazurin assays.

Janssen R&D Ireland




Zhengzhou University
CN 103304528 (2013)

Compound extracted from *Llicium henryi* antiviral activity against HBsAg and HBeAg antigens ($IC_{50} = 0.43$ and $0.5 \mu\text{M}$; in ELISA assays) and it also showed significant cytotoxicity ($TC_{50} = 3.28 \mu\text{M}$; using MTT method) in human hepatoma Hep G2 2.2.15 cells with therapeutic index values of 7.6 and 6.6, respectively.




Antivir Res 2014, 107: 6


BM601, a novel inhibitor of HBV



WO 1999058526




WO 2001038308




University of Maryland

Bioorg Med Chem Lett 2005, 15(24): 5397




US 2013059895

compound inhibited HBV-DNA
(IC_{50} =5.4 μ M and CC_{50} >100 μ M)




US 2014316132

Toll-like receptor TLR7 ligand that stimulated
IFN-alpha production in human peripheral blood
mononuclear cells (MEC = 0.03 μ M). Reported to
be useful for the treatment of HBV




these compounds dose-dependently
inhibit activity of HBV polymerase (by
42% at 1 mcg/ml) and also HCV
RNA-dependent RNA-polymerase
(NS5B, by 75% at 10 mcg/ml) *in vitro*




WO 1998033501

Gilead Sciences




WO 2011061590

antiviral activity in lymphoid MT2 cells infected with
92HT599-MT2 HIV-1 strain with 104.5 and 80.45%
inhibition at 1 and 0.1 μ M, respectively, and IC_{50}
values of 0.0117 and 0.0242 μ M, in p24 estimation
assays. It also showed cell viabilities of 99.97 and
89.93% at 1 and 0.1 mcM, respectively, against MT2
cells (CC_{50} >1 μ M), in MTT cytotoxicity assays




US 2015038515

CCC-0975, dose-dependently reduced
cccDNA (10, 20 and 70% reduction at
1, 3 and 10 mcM, respectively) and
DP-rcDNA levels in HepDES19 cells.




US 2009324544

Enanta Pharmaceuticals, Inc.




WO 2005095376


compound inhibited HBV
replication in 2.2.15 human
hepatoma cells with
respective EC_{50} and EC_{90}
values of 0.6 μ M and 3.4 μ M.




42nd Intersci Conf
Antimicrob Agents
Chemother (ICAAC)
(September 27-30, San
Diego) 2002, Abst F-1697




CN 102690262 (2012)



Bioorg Med Chem
2010, 18(14):
5048





WO 2002079187



CH-04522, inhibited HBV DNA
replication in HepG2 2.2.15 cells
with IC_{50} and CC_{50} values of 1.46
and 221.11 μ M (SI=151.06)


CN 102584690 (2012)

J Med Chem 2011, 54(16): 5660




WO 2007014023

compound inhibited HBV
proliferation in HepG2 cellular
assays (EC_{50} =0.01 μ M).



IC_{50} <1.1 μ M and SI>90.9

Arch Pharm 2011, 344(2): 78











EC_{50} =4 μ M, HBV-transfected
human Hep G2 cells

Topological analogues

ChemDiv Compounds (examples)









template



Topological analogues

ChemDiv Compounds (examples)

template



Topological analogues

ChemDiv Compounds (examples)

template

